首頁 > 市場調查報告書 > 製藥

婦科治療

市場調查報告書

商品編碼

1737158

女性健康藥品市場（按類型、藥物、應用和地區）：未來預測（2026-2032 年）

Pharmaceuticals For Women's Health Market By Type, By Drug, By Application And Region for 2026-2032

出版日期: 2025年05月09日 | 出版商:

Verified Market Research | 英文 202 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

女性健康藥品市場評估（2026-2032）

資訊和賦權的增加，使得女性對女性健康知識和計劃的需求日益成長，也使得女性更積極主動地尋求醫療干預措施來解決自身健康問題。這種意識的提升，也帶動了針對生殖健康、更年期管理和激素失衡等問題的藥物需求成長，使得該市場在2023年的銷售額預計將超過229.8904億美元，到2032年的估值將達到529.4094億美元。

日益成長的藥物介入需求主要針對女性健康。在理解和應對性別特異性健康挑戰方面，文化態度發生了顯著轉變，這促使人們更加倡導針對女性獨特生理和生殖需求的完整醫療保健解決方案。這種公眾觀念的改變促使製藥公司加大研發投入，專注於開發針對生殖健康問題、荷爾蒙失衡和更年期症狀等疾病的藥物和治療方法，從而使市場在2026年至2032年間的複合年成長率達到10.99%。

女性健康藥品市場：定義/概述

女性健康藥物是專門針對女性特有或主要影響女性的各種健康障礙或病症而設計的藥物和治療方法。這些藥物涵蓋一系列旨在改善生殖健康、荷爾蒙失衡、更年期症狀、避孕、生育治療以及主要影響女性的疾病（例如骨質疏鬆症和某些癌症）的產品。這些藥物旨在解決男性和女性之間的生理和荷爾蒙差異，以及女性一生中可能面臨的獨特健康挑戰和需求。

女性保健藥物用途廣泛，能夠滿足女性在人生不同階段的個人化生理和保健需求。從生殖健康到荷爾蒙平衡，藥物介入在治療各種疾病和提升整體健康水平方面發揮著至關重要的作用。

孕產婦護理領域的醫藥進步有望透過開發專注於產前問題、孕產婦營養和產前診斷的治療方法來改善妊娠結局和孕產婦福祉。從妊娠糖尿病的創新藥物到先進的產前篩檢技術，孕產婦醫學的未來有望降低風險，改善孕產婦和胎兒的健康，從而降低孕產婦的發病率和死亡率。

女性日益成長的生理問題是否會推動女性健康市場的發展？

女性生理問題的增加預計將對女性健康市場產生重大影響。許多人口群體開始意識到女性獨特的健康需求和擔憂，這推動了對旨在解決這些問題的專業醫療保健解決方案的需求。這種日益成長的意識，加上醫學研究和技術的進步，預計將推動女性健康產業的顯著成長。

全球女性生殖健康問題日益嚴重，是此趨勢背後的主要促進因素之一。不孕症、月經問題和生殖系統癌症已成為常見的健康問題，需要專家的介入和治療。此外，社會和生活方式的變化也使得人們更加重視計劃生育和生殖保健，從而刺激了對女性健康服務和產品的需求。女性生理問題的日益成長，加上社會觀念的轉變和技術的進步，很可能推動女性健康市場的顯著成長。

高成本是否會阻礙女性健康市場的發展？

研發成本是市場發展的一大障礙。發展和提升研發能力需要大量的資金投入，這可能會對許多市場化機構造成壓力。資金不足也阻礙了新醫療技術和系統的整合和維持。在基礎設施薄弱的地方，例如農村和低度開發地區，現代醫療設施和醫療設備的取得可能受到嚴重限制，阻礙了女性醫學及其他相關技術的傳播。

一個主要問題是女性醫療保健的高昂成本。這些成本涵蓋研發、製造和分銷等多個領域，所有這些都導致最終用戶支付更高的價格。如此高成本可能使許多人難以獲得這些醫療解決方案，尤其是在醫療保健服務難以覆蓋的低收入人群中。此外，新興國家對女性用藥物的相關性和可近性缺乏了解，加劇了市場滲透率和採用率有限的問題。

Siemens
Hologic, Inc.
Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
Abbott
BD
F. Hoffmann-La Roche Ltd
Thermo Fisher Scientific, Inc.
Koninklijke Philips NV
NeuroLogica Corp.
Shimadzu Medical pvt. Ltd.
GENERAL ELECTRIC.
Quest Diagnostics Incorporated
Sysmex India Pvt. Ltd
Hitachi Ltd.
Canon Inc.
FUJIFILM Holdings Corporation

第11章主要趨勢

產品發布/開發
企業合併與收購（M&A）
業務擴展
夥伴關係與合作

第12章附錄

相關分析

簡介目錄

Product Code: 54573

Pharmaceuticals For Women's Health Market Valuation - 2026-2032

The increasing need for knowledge and advocacy for women's health issues with more information and empowerment, women are becoming more proactive in seeking medical interventions to address their health concerns. This increased awareness has resulted in a growing demand for pharmaceutical medications designed to address issues such as reproductive health, menopausal management, and hormonal imbalances by enabling the market to surpass a revenue of USD 22989.04 Million in 2023 and reach a valuation of around USD 52940.94 Million by 2032.

The increasing need for medicinal interventions is aimed only at women's health. There has been a significant shift in cultural attitudes toward understanding and addressing gender-specific health challenges resulting in increased advocating for complete healthcare solutions targeted to women's distinct physiological and reproductive needs. This changing public discourse has encouraged pharmaceutical companies to invest in research and development efforts focused on creating medicines and therapies for diseases such as reproductive health issues, hormonal imbalances, and menopausal symptoms by enabling the market to grow at a CAGR of 10.99% from 2026 to 2032.

Pharmaceuticals For Women's Health Market: Definition/ Overview

The term pharmaceuticals for women's health refers to medications and treatments that are specifically designed to address various health disorders and conditions that are unique to or mostly affect women. These medications may include a wide range of products aimed at improving reproductive health, hormonal imbalances, menopausal symptoms, contraception, fertility therapies, and illnesses such as osteoporosis and some types of cancer that primarily affect women. These medications are designed to address the different biological and hormonal differences between men and women as well as the unique health difficulties and needs that women may confront throughout their lifetimes.

The pharmaceuticals for women's health include a wide range of applications that address the individual physiological and healthcare demands of women at various phases of life. From reproductive health to hormonal balance and beyond pharmaceutical interventions play an important role in treating a variety of medical disorders and boosting overall well-being.

The pharmaceutical advances in maternal care are expected to improve pregnancy outcomes and maternal well-being by developing focused therapies for prenatal problems, maternal nutrition, and prenatal diagnostics. From innovative treatment agents for gestational diabetes to advanced prenatal screening technologies, the future of maternal pharmaceuticals holds promise for decreasing risks and improving mother-fetal health outcomes; therefore, reducing maternal morbidity and mortality rates.

Will the Increasing Prevalence of Women's Biological Concerns Drive the Women's Health Market?

The increasing number of women's biological problems is predicted to have an important effect on the female health market. Across many demographic segments, there is a growing acknowledgment of women's particular health demands and concerns increasing demand for specialized healthcare solutions designed to address these issues. This increased awareness together with advances in medical research and technology is expected to fuel significant growth in the women's health industry.

The rising incidence of reproductive health difficulties and concerns among women around the world is one of the key causes driving this trend. Infertility, menstrual problems, and reproductive cancers have arisen as common health issues that require specialist interventions and treatments. Also, social and lifestyle changes have resulted in a greater focus on family planning and reproductive healthcare increasing demand for women's health services and products. The increasing prevalence of women's biological concerns, coupled with evolving social attitudes and technological advancements is controlled to drive significant growth within the women's health market.

Will the High Cost Associated with Research and Development Hamper the Women's Health Market?

The costs associated with research and development efforts present a significant barrier to market advancement. Developing and improving R&D proficiency requires significant financial dedication which may put pressure on many market-based organizations. Also, inadequate funding creates obstacles to integrating and maintaining new medical technologies and systems. Access to contemporary medical facilities and equipment may be severely limited in locations with inadequate infrastructure such as rural or underdeveloped areas hindering the widespread adoption of women's medicine and other associated technology.

The major issue is the high expense of women's medicine. These expenses cover a wide range of areas including research and development, manufacturing, and distribution all of which contribute to higher prices for end users. Such high costs may make these medical solutions inaccessible to a large segment of the population particularly in low-income areas where healthcare affordability is a major concern. Furthermore, a lack of understanding about the significance and availability of women's medicine in developing countries exacerbates the problem of limiting market penetration and adoption rates.

Category-Wise Acumens

Will the Increasing Prevalence of Women's Biological Concerns Drive the Pharmaceuticals For Women's Health Market?

The drugs for women's health industry are expected to increase rapidly as women's biological issues become more prevalent. This rising trend is driven by a variety of factors ranging from shifting opinions in society to advances in medical science and technology. Passive variables such as cultural developments toward recognizing and addressing women's health issues are critical in increasing demand for pharmaceutical solutions customized specifically to women's needs. Also, the acknowledgment and understanding of the unique biological obstacles that women experience at various phases of their lives has prompted increased research and development activities in the pharmaceutical business.

The increasing focus on women's health is highlighted by the rising occurrence of illnesses such as hormonal imbalances, reproductive health issues, and menopausal symptoms, all of which require specialist treatment choices. Also, women's growing understanding and empowerment about their health and well-being have fueled the desire for pharmaceutical therapies that address their unique physiological demands. In addition, regulatory actions targeted at encouraging women to participate in clinical trials and healthcare policy have contributed to the development and availability of medications that address women's health concerns. Therefore, the Pharmaceuticals For Women's Health Market is expected to grow significantly as it continues to serve women's evolving healthcare demands around the world.

Will the Risk of Osteoporosis Fractures Support the Growth of the Women's Health Market?

The risk of osteoporosis fractures is anticipated to contribute significantly to the expansion of the women's health market. Within this domain, a multitude of factors converge to underscore the critical importance of addressing osteoporosis as a prevalent health concern among women. Passive lifestyle patterns, hormonal changes associated with menopause, and genetic predispositions collectively elevate the vulnerability of women to osteoporotic fractures. This heightened susceptibility not only poses significant health risks but also imposes substantial economic burdens on healthcare systems worldwide.

The increased awareness of osteoporosis-related fractures has increased demand for enhanced diagnostic technology and novel treatment options. This has sparked significant research and development activities aiming at improving the efficacy of current medicines while also exploring new therapeutic approaches. Passive support for market expansion comes from the growing use of evidence-based recommendations and clinical procedures that stress proactive screening and early intervention measures.

Country/Region-wise Acumens

Will the Increasing Investment in Research and Development be the Opportunistic Factor for North America?

North America is expected to continue establishing its dominance in the worldwide Pharmaceuticals For Women's Health Market as it currently holds the greatest market share. This dominance can be given to numerous variables. There has been a noticeable increase in focus to women's therapeutics in the region demonstrating a greater awareness and prioritization of women's health concerns. This increased attention is accompanied by a similar increase in funding for the research and development of novel treatments, techniques, and medications to address women's health concerns. Such expenditures demonstrate a commitment to advance medical science and improve healthcare outcomes for women of all ages and medical conditions.

The presence of world-class medical institutes and healthcare facilities strengthens North America's leadership in pharmaceuticals for women's health. Healthcare professionals and researchers in the region have access to a variety of experience, resources, and innovative technology, allowing them to drive innovation and offer superior healthcare results for female patients. This excellent ecosystem promotes collaboration, knowledge exchange, and the quick translation of scientific discoveries into clinical applications putting North America at the forefront of the global pharmaceutical landscape for women's health.

Therefore, North America's dominance in the Pharmaceuticals For Women's Health Market is based on several factors including an increased focus on women's therapeutics, significant investments in research and development, a commitment to safety measures, an increase in the prevalence of women's health conditions, and the presence of world-class medical institutions.

How will the Pharmaceuticals For Women's Health Market Favor in Asia Pacific?

Demographic dynamics such as population increase, aging populations, and changing lifestyles all contribute to the region's growing demand for women's health drugs. As the population ages, there is a greater need for therapies and drugs that address menopausal symptoms, osteoporosis, and other age-related illnesses impacting women. Also, lifestyle variables such as increased stress, sedentary lifestyles, and changing eating habits contribute to the development of obesity, diabetes, and cardiovascular disease in women boosting demand for relevant pharmaceutical therapies.

The advancement in medical research and technology is projected to drive innovation in women's health pharmaceuticals resulting in the creation of new medications and cures. This includes advances in reproductive health, contraception, fertility therapies, and gynecological diseases like endometriosis and polycystic ovary syndrome. Pharmaceutical company's continuous efforts to invest in research and development primarily aimed at women's health issues are expected to help market expansion in Asia Pacific.

The medicines for women's health market in the Asia Pacific is expected to expand due to a variety of factors. The region's increasing focus on healthcare and well-being combined with increased awareness of women's health challenges is expected to drive demand for pharmaceutical goods modified to women's special needs. This increased awareness is supported by the efforts of governments, healthcare institutions, and advocacy organizations that are actively advocating measures to address women's health issues.Competitive Landscape

The Pharmaceuticals For Women's Health Market is a dynamic and competitive space, characterized by a diverse range of players vying for market share. These players are on the run for solidifying their presence through the adoption of strategic plans such as collaborations, mergers, acquisitions, and political support. The organizations are focusing on innovating their product line to serve the vast population in diverse regions.

Some of the prominent players operating in the Pharmaceuticals For Women's Health Market include:

Siemens, Hologic Inc., Shenzhen Mindray Bio-Medical Electronics Co. Ltd., Abbott, BD, Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc., Koninklijke Philips N.V., NeuroLogica Corp., Shimadzu Medical pvt. Ltd., GENERAL ELECTRIC, Quest Diagnostics Incorporated, Sysmex India Pvt. Ltd., Hitachi Ltd., Canon Inc., FUJIFILM Holdings Corporation

Latest Developments

In December 2020, Pfizer, Inc., and Myovant Sciences worked on the commercialization and development of Relugolix, the first and only oral GnRH antagonist for oncology and women's health.

In September 2020, Bayer increased its range of women's healthcare products by acquiring KaNDy Therapeutics Ltd. Menopausal vasomotor symptoms affect up to 75% of women who are transitioning into menopause. These symptoms can disrupt both their professional and private life and are devastating for several years for people affected, resulting in major additional healthcare and economic costs.

1 INTRODUCTION OF GLOBAL PHARMACEUTICALS FOR WOMEN'S HEALTH MARKET

1.1 Overview of the Market
1.2 Scope of Report
1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

3.1 Data Mining
3.2 Validation
3.3 Primary Interviews
3.4 List of Data Sources

4 GLOBAL PHARMACEUTICALS FOR WOMEN'S HEALTH MARKET OUTLOOK

4.1 Overview
4.2 Market Dynamics
- 4.2.1 Drivers
- 4.2.2 Restraints
- 4.2.3 Opportunities
4.3 Porters Five Force Model
4.4 Value Chain Analysis

5 GLOBAL PHARMACEUTICALS FOR WOMEN'S HEALTH MARKET, BY TYPE

5.1 Overview
5.2 Drugs
5.3 Devices

6 GLOBAL PHARMACEUTICALS FOR WOMEN'S HEALTH MARKET, BY APPLICATION

6.1 Overview
6.2 Hormonal Infertility
6.3 Postmenopausal Osteoporosis
6.4 Endometriosis
6.5 Contraceptives
6.6 Menopause
6.7 Polycystic Ovary Syndrome

7 GLOBAL PHARMACEUTICALS FOR WOMEN'S HEALTH MARKET, BY DRUG

7.1 Overview
7.2 Prolia
7.3 XGEVA
7.4 EVISTA
7.5 Mirena
7.6 Zometa
7.7 Reclast or Aclasta
7.8 Minastrin 24 Fe
7.9 FORTEO
7.10 NuvaRing
7.11 Primarin
7.12 ACTONEL
7.13 ORTHO TRI-CY LO (28)

8 GLOBAL PHARMACEUTICALS FOR WOMEN'S HEALTH MARKET, BY GEOGRAPHY

8.1 Overview
8.2 North America
- 8.2.1 U.S.
- 8.2.2 Canada
- 8.2.3 Mexico
8.3 Europe
- 8.3.1 Germany
- 8.3.2 U.K.
- 8.3.3 France
- 8.3.4 Rest of Europe
8.4 Asia Paciic
- 8.4.1 China
- 8.4.2 Japan
- 8.4.3 India
- 8.4.4 Rest of Asia Pacific
8.5 Rest of the World
- 8.5.1 Latin America
- 8.5.2 Middle East and Africa

9 GLOBAL PHARMACEUTICALS FOR WOMEN'S HEALTH MARKET COMPETITIVE LANDSCAPE

9.1 Overview
9.2 Company Market Ranking
9.3 Key Development Strategies

10 COMPANY PROFILES

10.1 Siemens
- 10.1.1 Overview
- 10.1.2 Financial Performance
- 10.1.3 Product Outlook
- 10.1.4 Key Developments
10.2 Hologic, Inc.
- 10.2.1 Overview
- 10.2.2 Financial Performance
- 10.2.3 Product Outlook
- 10.2.4 Key Developments
10.3 Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
- 10.3.1 Overview
- 10.3.2 Financial Performance
- 10.3.3 Product Outlook
- 10.3.4 Key Developments
10.4 Abbott
- 10.4.1 Overview
- 10.4.2 Financial Performance
- 10.4.3 Product Outlook
- 10.4.4 Key Developments
10.5 BD
- 10.5.1 Overview
- 10.5.2 Financial Performance
- 10.5.3 Product Outlook
- 10.5.4 Key Developments
10.6 F. Hoffmann-La Roche Ltd
- 10.6.1 Overview
- 10.6.2 Financial Performance
- 10.6.3 Product Outlook
- 10.6.4 Key Developments
10.7 Thermo Fisher Scientific, Inc.
- 10.7.1 Overview
- 10.7.2 Financial Performance
- 10.7.3 Product Outlook
- 10.7.4 Key Developments
10.8 Koninklijke Philips N.V.
- 10.8.1 Overview
- 10.8.2 Financial Performance
- 10.8.3 Product Outlook
- 10.8.4 Key Developments
10.9 NeuroLogica Corp.
- 10.9.1 Overview
- 10.9.2 Financial Performance
- 10.9.3 Product Outlook
- 10.9.4 Key Developments
10.10 Shimadzu Medical pvt. Ltd.
- 10.10.1 Overview
- 10.10.2 Financial Performance
- 10.10.3 Product Outlook
- 10.10.4 Key Developments
10.11 GENERAL ELECTRIC.
- 10.11.1 Overview
- 10.11.2 Financial Performance
- 10.11.3 Product Outlook
- 10.11.4 Key Developments
10.12 Quest Diagnostics Incorporated
- 10.12.1 Overview
- 10.12.2 Financial Performance
- 10.12.3 Product Outlook
- 10.12.4 Key Developments
10.13 Sysmex India Pvt. Ltd
- 10.13.1 Overview
- 10.13.2 Financial Performance
- 10.13.3 Product Outlook
- 10.13.4 Key Developments
10.14 Hitachi Ltd.
- 10.14.1 Overview
- 10.14.2 Financial Performance
- 10.14.3 Product Outlook
- 10.14.4 Key Developments
10.15 Canon Inc.
- 10.15.1 Overview
- 10.15.2 Financial Performance
- 10.15.3 Product Outlook
- 10.15.4 Key Developments
10.16 FUJIFILM Holdings Corporation
- 10.16.1 Overview
- 10.16.2 Financial Performance
- 10.16.3 Product Outlook
- 10.16.4 Key Developments6